Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry

Azacitidine can be effective in myelodysplastic syndromes (MDS) associated with inflammatory/autoimmune diseases. Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) is a new monogenic autoinflammatory syndrome caused by somatic ubiquitin‐like modifier‐activating enzyme 1 (UBA1) mutation, often associated with MDS, whose treatment is difficult and not yet codified. Based on a French nationwide registry of 116 patients with VEXAS, we report the efficacy and safety of azacitidine treatment in 11 patients with VEXAS with MDS. Clinical response of VEXAS to azacitidine was achieved in five patients (46%), during 6, 8+, 12, 21, 27+ months respectively, suggesting that azacitidine can be effective in selected patients with VEXAS and associated MDS.

[1]  D. Kastner,et al.  Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. , 2021, Blood advances.

[2]  Y. Kirino,et al.  Tocilizumab in VEXAS relapsing polychondritis: a single-center pilot study in Japan , 2021, Annals of the Rheumatic Diseases.

[3]  L. Terriou,et al.  Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease. , 2021, The New England journal of medicine.

[4]  S. Mustjoki,et al.  Somatic Mutations in "Benign" Disease. , 2021, The New England journal of medicine.

[5]  A. Hoischen,et al.  Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of VEXAS patients. , 2021, The Journal of allergy and clinical immunology.

[6]  N. Young,et al.  VEXAS syndrome , 2021, Blood.

[7]  P. Evans,et al.  Novel somatic mutations in UBA1 as a cause of VEXAS syndrome , 2021, Blood.

[8]  E. Clappier,et al.  Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease , 2021, Leukemia.

[9]  F. Barraco,et al.  Therapeutic options in Vexas syndrome: insights from a retrospective series. , 2021, Blood.

[10]  J. Mullikin,et al.  Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. , 2020, The New England journal of medicine.

[11]  N. Vey,et al.  Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review. , 2019, Autoimmunity reviews.

[12]  P. Fenaux,et al.  Autoimmune manifestations associated with myelodysplastic syndromes , 2018, Annals of Hematology.

[13]  O. Decaux,et al.  Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Running title : Azacitidine in autoimmune disorders associated with MDS / CMML , 2018 .

[14]  S. Scholl,et al.  Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5‐azacytidine and literature review , 2014, European journal of haematology.

[15]  L. Rink,et al.  Regulation of the Interleukin-6 gene expression during monocytic differentiation of HL-60 cells by chromatin remodeling and methylation. , 2014, Immunobiology.

[16]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[17]  P. Vyas,et al.  Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). , 2012, Blood.

[18]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.